한글목차

세계 폴리오 백신 시장 전망은 유망하며, VAPP, VDPV 시장에 기회가 있습니다. 세계 소아마비 백신 시장은 2025-2031년 연평균 2.3%의 성장률을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 예방접종에 대한 인식과 정기적인 예방접종의 필요성, 정부 및 단체의 강력한 자금 지원 및 지원입니다.

• Lucintel의 예측에 따르면 유형별로는 경구용 소아마비 백신이 예측 기간 중 높은 성장세를 보일 것으로 예측됩니다. 이는 주사바늘을 사용하지 않고 쉽게 접종할 수 있는 경구용 소아마비 백신에 대한 수요가 증가함에 따라 경구용 소아마비 백신의 사용이 증가하고 있기 때문입니다.
• 용도별로는 VDPV 발생에 대한 우려가 높아지고, 표적화된 백신 접종 전략에 대한 수요가 증가함에 따라 VDPV가 높은 성장세를 보일 것으로 예측됩니다.
• 지역별로는 북미가 예측 기간 중 가장 높은 성장세를 보일 것으로 예측됩니다.

소아마비 백신 시장의 새로운 동향

세계 소아마비 백신 시장은 백신 제제, 유통, 예방접종 계획과 관련된 새로운 도전과 새로운 기회가 존재하므로 끊임없이 변화하고 있습니다. 최근 동향은 소아마비 퇴치를 위한 끊임없는 노력, 소외된 지역에서 사용 가능한 백신의 범위 확대, 백신 유래 소아마비 바이러스의 발병 문제 해결에 초점을 맞추었습니다. 다음은 세계 소아마비 백신 시장을 형성하는 5가지 새로운 동향입니다.

• 불활성화 소아마비 백신 자동화의 진전: 백신 유래 소아마비 바이러스(VDPV)의 지표 사례가 전 세계에서 경종을 울리는 가운데, 대부분의 국가에서 경구용 소아마비 백신(OPV)에서 IPV로의 전환이 진행되고 있습니다. IPV는 VDPV의 위험은 사라지지만 면역력은 유지되므로 소아마비 퇴치를 확실히 달성하는 데 중요한 역할을 합니다. 이 전환은 예방접종률이 낮고 의료 인프라가 취약한 지역에서 가장 중요합니다. 다시 소아마비가 발생할 가능성을 최소화하면서 안전하고 장기적으로 소아마비 면역을 유지할 수 있다는 점에서 IPV 세계 시장은 확대되고 있습니다.
• 감시 및 모니터링에 대한 중요성 증대: 전 세계 소아마비 퇴치를 목표로 소아마비 바이러스 감염을 감지하고 모니터링하기 위한 감시 시스템을 강화할 필요성이 높아지고 있습니다. 감시에는 바이러스의 유전적 구조뿐만 아니라 사건 보고 및 백신 접종률 추적 개선도 포함됩니다. 이미 수년간 소아마비가 발생하지 않은 국가라도 백신 접종률이 낮거나 이민자가 많아 소아마비가 발생할 위험이 있는 경우 감시가 필수적입니다. 이러한 감시 강화는 발병을 조기에 발견하고 조기 개입을 통해 감염 확산을 막는 데 매우 중요합니다.
• 다른 국가 전략과 연계한 백신 접종 실시: 일부 국가에서는 소아마비 예방접종 보급률을 높이는 동시에 활동비용을 절감하기 위해 이 전략을 활용하고 있습니다. 이러한 통합적 접근은 소아마비 예방접종에 홍역과 B형 간염 예방접종을 결합하거나, 예방접종을 받아야 하는 어린이들에게 각종 정기 백신 공급을 개선하여 보급률을 높이는 것을 목표로 하고 있습니다. 이는 의료시설까지의 거리가 먼 저소득 지역이나 지원의 손길이 닿기 어려운 지역에서 더욱 중요한 추세가 되고 있습니다. 어린이를 이용 가능한 프로그램에 포함시키는 것은 일반적인 예방접종 시스템과 공중보건 시스템을 개선하는 데에도 도움이 됩니다.
• 새로운 유형의 소아마비 백신 개발: 새로운 혼합 백신과 개량형 백신의 개발이 진행되고 있습니다. 이러한 백신은 면역반응을 개선하고, 백신의 운반을 용이하게 하며, 운송 및 보관에 필요한 안정성을 향상시킬 것으로 기대되고 있습니다. 새로운 보조제 및 전달 시스템, 그리고 소아용 백신과 다른 백신과의 혼합 백신 등 소아에게 투여되는 백신도 연구되고 있습니다. 이러한 기술 혁신은 특히 물류 제약이 있는 지역이나 새로운 발생 패턴이 나타나는 지역에서 더 나은 대안을 제공할 수 있습니다.
• 민간 부문과 민관 파트너십: 전 세계 소아마비 예방접종 캠페인에 민간 기업의 참여가 증가하고 있으며, 제약회사는 백신 제조, 마케팅, 연구에 투자하고 있습니다. 민관 파트너십은 특히 자원이 부족한 환경에서 소아마비 퇴치 전략을 보완하는 데 효과적입니다. 이러한 협력 관계는 중저소득 국가를 위한 백신 재고 및 가격 책정 개발을 지원하고, 전 세계 소아마비 퇴치 활동을 강화하는 데 도움이 될 것입니다.

세계가 소아마비 퇴치라는 목표를 향해 빠르게 나아가고 있는 가운데, IPV의 사용, 감시 개선, 예방접종 프로그램에 백신을 통합하는 등 세계 소아마비 백신 시장의 새로운 동향이 강하게 나타나고 있습니다. 이러한 추세는 백신의 접근성을 높이고, 소아마비 백신의 안전성을 향상시키며, 전 세계에서 투여 효율을 개선하고 있습니다. 또한 민관 파트너십의 경우와 마찬가지로 새로운 유형의 백신과 그 개발은 대규모 예방접종 캠페인의 물류 및 재정적 제약을 극복하는 데 도움이 되고 있습니다.

소아마비 백신 시장의 최근 동향

세계 소아마비 백신 시장의 최근 변화는 IPV 부스터 용량 도입, 생산 혁신, 유통 혁신, 국제 협력 등 세계 소아마비 퇴치 캠페인의 성공에 필수적인 요소에 주목하게 하는 의도적인 변화입니다. 소아마비 예방접종 전략 개발의 진전은 세계 소아마비 퇴치 및 백신 유래 균주 퇴치라는 최종 목표에 기여하고, 예방접종률을 높이고, 비대표자를 포함시키는 데 기여할 것입니다. 다음은 세계 소아마비 백신 시장 전망를 형성할 5가지 주요 발전입니다.

• OPV에서 IPV로의 전환: 경구용 소아마비 백신(OPV)에서 불활성화 소아마비 백신(IPV)으로의 전환은 소아마비 백신 시장의 큰 변화 중 하나입니다. IPV에서는 OPV의 과제였던 백신 관련 소아마비 바이러스(VAP)의 위험이 없습니다. 이 변경은 WHO 및 기타 보건 기관에서 면역력을 안전하게 강화하기 위해 제안한 것입니다. IPV 예방접종은 세계 박멸 캠페인의 목표를 달성하기 위해 각국의 예방접종 일정에 포함되어 있습니다.
• 정기 예방접종 일정에서 IPV 사용 개선: 인도, 중국 등의 국가에서는 이미 IPV를 정기 예방접종 프로그램에 포함시켜 소아마비 퇴치에 도움을 주고 있습니다. 박멸의 마지막 단계에서 IPV와 OPV를 병용함으로써 VDPV 발생의 위협을 증가시키지 않고 주민의 면역력을 유지할 수 있었습니다. 이 두 가지 접근 방식은 서로를 보완하고 예방접종 캠페인을 강화하며 소아마비 재발을 예방하는 데 도움이 되고 있습니다.
• 감시 시스템 강화: 소아마비 감염은 보다 엄격한 감시 시스템을 통해 효과적으로 억제되고 있습니다. 소아마비 바이러스의 유전자 염기서열 결정, 보고 시스템 개선, 실시간 정보 등은 소아마비 발생을 조기에 발견하는 데 필수적인 요소로 작용하고 있습니다. 이러한 발전은 특히 발병 국가들에서 신속한 대응책을 마련하고 예방접종을 가능한 한 빨리 시행할 수 있도록 하는 데 도움이 되었습니다. 이를 통해 새로운 소아마비 발병을 놓치지 않고 소아마비 퇴치를 위한 최종 추진력을 강화할 수 있습니다.
• 소아마비 퇴치 활동에 대한 전 세계 기여 확대: 세계보건기구, 정부, 민간단체로부터 많은 자금이 지원되고 있으며, 특히 세계소아마비퇴치추진계획(GPEI) 등의 프로젝트를 지원하고 있습니다. 이러한 투자로 인해 백신 부족 지역이나 분쟁 지역에서도 백신 판매 캠페인과 투여가 촉진되고 있습니다. 보건 인프라 강화와 재정적 지원은 예방접종 프로그램의 성공에 크게 기여했으며, 소아마비는 세계 보건의 초점이 되고 있습니다.
• 접근성 높은 백신을 위한 민관 파트너십: GSK와 사노피와 같은 기업은 국제보건기구와 협력하여 많은 저소득층과 의료서비스가 부족한 지역에서 소아마비 백신을 쉽게 접종할 수 있도록 하는 데 중요한 역할을 하고 있습니다. 이 구상은 높은 비용, 물류 문제, 불충분한 의료 서비스 제공 등의 장벽을 극복하여 더 많은 국가에서 백신을 접종할 수 있도록 하는 것을 목표로 합니다. 이러한 협력 관계는 백신 재고 개발, 유통 개선, 세계 백신 제조 활동 확대에 도움이 되고 있습니다.

세계 소아마비 백신 시장의 최근 개발 동향은 소아마비 퇴치에서 전환, 감시, 자금 조달 및 협력 체제의 중요성을 강조하고 있습니다. IPV 도입 지원, 감시 개선, 민관 협력을 통해 전 세계 백신 접종 추진이 강화되고 있습니다. 이러한 노력과 백신 관련 과제 및 발병에 대한 대응이 결합되어 세계는 소아마비 퇴치에 한 걸음 더 다가서고 있습니다. 시장은 현재 전 세계에서 지속적인 예방접종 및 감시 프로그램을 실시하여 소아마비 퇴치를 확실히 유지하는 데 초점을 맞추었습니다.

목차

제1장 개요

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 폴리오 백신 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• 폴리오 백신 I : 동향과 예측(2019-2031년)
• 폴리오 백신 II : 동향과 예측(2019-2031년)
• 폴리오 백신 III : 동향과 예측(2019-2031년)
• 경구 폴리오 백신 : 동향과 예측(2019-2031년)

제5장 세계의 폴리오 백신 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• VAPP : 동향과 예측(2019-2031)
• VDPV : 동향과 예측(2019-2031)

제6장 지역 분석

• 개요
• 세계의 폴리오 백신 시장 : 지역별

제7장 북미의 폴리오 백신 시장

• 개요
• 북미의 폴리오 백신 시장 : 유형별
• 북미의 폴리오 백신 시장 : 용도별
• 미국의 폴리오 백신 시장
• 멕시코의 폴리오 백신 시장
• 캐나다의 폴리오 백신 시장

제8장 유럽의 폴리오 백신 시장

• 개요
• 유럽의 폴리오 백신 시장 : 유형별
• 유럽의 폴리오 백신 시장 : 용도별
• 독일의 폴리오 백신 시장
• 프랑스의 폴리오 백신 시장
• 스페인의 폴리오 백신 시장
• 이탈리아의 폴리오 백신 시장
• 영국의 폴리오 백신 시장

제9장 아시아태평양의 폴리오 백신 시장

• 개요
• 아시아태평양의 폴리오 백신 시장 : 유형별
• 아시아태평양의 폴리오 백신 시장 : 용도별
• 일본의 폴리오 백신 시장
• 인도의 폴리오 백신 시장
• 중국의 폴리오 백신 시장
• 한국의 폴리오 백신 시장
• 인도네시아의 폴리오 백신 시장

제10장 기타 지역(ROW)의 폴리오 백신 시장

• 개요
• 기타 지역(ROW) 폴리오 백신 시장 : 유형별
• 기타 지역(ROW) 폴리오 백신 시장 : 용도별
• 중동의 폴리오 백신 시장
• 남미의 폴리오 백신 시장
• 아프리카의 폴리오 백신 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간 경쟁 관계
  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계의 폴리오 백신 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증·라이선싱
  • 기업인수합병(M&A), 계약, 제휴, 합병사업

제13장 밸류체인에서 주요 기업의 기업 개요

• Competitive Analysis
• GSK
• Sanofi-Pasteur
• Merck
• Crucell
• China National Biotech Group

제14장 부록

• 도표 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global poliomyelitis vaccine market looks promising with opportunities in the VAPP, VDPV markets. The global poliomyelitis vaccine market is expected to grow with a CAGR of 2.3% from 2025 to 2031. The major drivers for this market are the growing awareness about immunization and the need for routine vaccinations, and the strong funding and support from governments and organizations.

• Lucintel forecasts that, within the type category, the oral poliomyelitis vaccine is expected to witness higher growth over the forecast period due to the growing demand for easy-to-administer and needle-free vaccination options, which is boosting oral polio vaccine use.
• Within the application category, VDPV is expected to witness higher growth due to rising concerns over VDPV outbreaks, which are driving demand for targeted vaccination strategies.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market is constantly changing as there are new challenges and new opportunities when it comes to vaccine formulation, distribution, and immunization plans. The recent trends are targeting the perpetual efforts to eradicate polio, widening the scope of available vaccines in neglected areas, and addressing the problems of outbreaks of vaccine-derived poliovirus. Below are five emerging trends that are persistent in the shaping of the global poliomyelitis vaccine market.

• Increasing automation of the inactivated polio vaccine: As the vaccine-derived poliovirus (VDPV) index cases have raised alarm bells around the world, most countries are transitioning from oral polio vaccine (OPV) to IPV. IPV also removes the VDPV risk but preserves immunity, which remains critical in ensuring that polio eradication is achieved. This transition is most relevant in regions with poor immunization rates and weak healthcare infrastructure. The world market for IPV is expanding owing to its ability to provide safe and long-term immunity against polio with minimal chances of another outbreak.
• Growing emphasis on surveillance and monitoring: With the goal of eradicating polio from the entire globe, there is an increasing need to strengthen the surveillance system to detect and monitor poliovirus transmission. Surveillance includes not only the genetic makeup of the virus but also improvements in the reporting of events and tracking vaccination coverage. Surveillance is vital even for countries that have already been polio-free for years but pose risks due to low vaccination coverage or migration patterns. These enhancements are critical for the early detection of outbreaks and limiting potential spread through early interventions.
• Vaccination deliveries linked with other national strategies: Some countries are using this strategy to improve the coverage of polio vaccination while at the same time reducing operational expenditures. Such integrated approaches target increased coverage by interspersing polio vaccinations with measles or hepatitis B and improving the availability of various routine vaccines to children, which would otherwise go unvaccinated. This is becoming a more crucial trend in low-income and hard-to-reach areas where distances to healthcare facilities are vast. Integrating children into available programs also improves the general immunization system and the public health systems.
• Development of new types of polio vaccines: Novel combination vaccines and improved formulations are under development. These vaccines are expected to improve the immune response, ease vaccine delivery, and improve stability features required for transport and storage. New adjuvants or delivery systems, as well as combined vaccines, e.g., polio with other vaccines administered to children, are being investigated. Such innovations may offer better options, especially in areas that have logistical constraints or where there are new patterns of outbreaks.
• Private sector and public-private partnerships: Participation of the private sector in the global polio vaccination campaign has risen, with pharmaceutical companies investing towards vaccine manufacturing, marketing, and research. Public-private partnerships are effective in complementing polio eradication strategies, particularly in resource-constrained settings. Such collaborations assist in developing vaccine stocks and pricing for lower- and middle-income countries, thus enhancing global polio eradication efforts.

As the world moves rapidly towards the goal of eradicating polio, trends such as the usage of IPV, improved issues on surveillance, or the streamlining of vaccines with immunization programs are strong emerging trends in the global poliomyelitis vaccine market. These trends are enhancing the availability of vaccines, increasing the safety of polio vaccines, and improving the efficiency of administration worldwide. And, as in the case of public-private partnerships, new types of vaccines and their development are helping to overcome logistical and financial constraints on wide-scale immunization campaigns.

Recent Developments in the Poliomyelitis Vaccine Market

The latest changes in the global poliomyelitis vaccine market are purposeful, as they draw attention to factors such as the introduction of an IPV booster dose, production innovations, distribution innovations, and international cooperation, which are crucial for the global success of the polio eradication campaign. Progress in the development of polio vaccination strategies contributes to the targeted end goal, which is the global eradication of polio and elimination of vaccine-derived strains, increasing vaccination coverage, and including non-represented people. Below are five key developments shaping the future of the global poliomyelitis vaccine market.

• Global move from OPV usage towards IPV: The global movement from the use of oral polio vaccine (OPV) to inactivated polio vaccine (IPV) is one of the major changes in the poliomyelitis vaccine market. With IPV, countries do not have the risk of vaccine-associated poliovirus (VAP), which was a challenge with OPV in some settings. This change is advocated by WHO and other health organizations to enhance immunity safely. IPV doses are incorporated into national immunization schedules to keep the objectives of the global eradication campaign on track.
• IPV use improved in routine immunization schedules: Countries like India, China, and others have already incorporated IPV into their routine vaccination programs, aiding in the fight against polio. The use of IPV with OPV during the last stages of eradication has helped maintain population immunity without heightening the threat of VDPV outbreaks. The two approaches supplement each other and help enhance vaccination campaigns, preventing re-emergence of polio.
• Enhanced systems of surveillance: The transmission of polio has been effectively controlled through stricter surveillance systems. Polio virus strain genetic sequencing, improved reporting systems, and real-time information have become indispensable for early detection of outbreaks. Such advancements allow for rapid response measures, especially in countries where outbreaks have occurred, ensuring that immunization takes place as quickly as possible. This guarantees that no new cases of polio are missed and strengthens the final push to end the disease.
• Greater contributions worldwide for polio eradication efforts: Significant funding from global health organizations, governments, and private entities has been received, notably supporting projects like the Global Polio Eradication Initiative (GPEI). These investments facilitate vaccine marketing campaigns and administration, even in rare and conflict-hit areas. Reinforcing health infrastructure and financial backing has significantly contributed to the success of vaccination programs and kept polio as a focus in global health.
• Public-private partnerships for accessible vaccines: Companies like GSK, Sanofi, and others working with international health organizations have played a key role by making polio vaccines available and affordable in many low-income and underserved areas. Efforts aim to make vaccine access possible in more countries by overcoming barriers such as high costs, logistical issues, and inadequate healthcare provision. Such collaborations help develop vaccine stocks, improve distribution, and expand global vaccine manufacturing activities.

Recent developments in the global poliomyelitis vaccine market highlight the importance of transitions, surveillance, funding, and collaborations in the fight against polio. Support for IPV introduction, improved surveillance, and public-private partnerships have enhanced the global push for vaccination. These efforts, combined with addressing vaccine-related challenges and outbreaks, are bringing the world closer to the elimination of polio. The market now focuses on ensuring that polio remains eradicated through sustained immunization and surveillance programs worldwide.

Strategic Growth Opportunities in the Poliomyelitis Vaccine Market

The world's poliomyelitis vaccine market is experiencing acceleration in development owing to challenges posed to polio eradication: mass vaccinations, improvements in vaccine development and dissemination, global cooperation, etc. Now that polio has been eradicated in most places, the challenge is to eliminate this disease entirely and focus on new challenges. The market is still developing and offers possibilities for new strategies in producing, distributing, and monitoring vaccines. In particular, with most countries switching from the oral form of the polio vaccine to the inactivated type, here are five growth opportunities that will cut across sectors in the poliomyelitis vaccine market.

• Increasing usage of IPV within routine immunization schedules: The transition from OPV to IPV brings potential for increased revenue. IPV offers enhanced safety as residual VDPV is absent. Continued use of IPV in countries that have achieved polio-free status will help protect against resurgence. This change necessitates increased capacity in vaccine manufacturing, cold chain logistics, and regulatory frameworks, providing growth avenues for manufacturers and health organizations.
• The use of combination vaccines to eradicate polio circulation: Including polio vaccines in DTP (diphtheria, tetanus, pertussis) vaccines enhances the market. Combining polio vaccination with wider immunization activities lowers operational costs and raises coverage. This strategy stimulates demand for combination vaccines, which is cost-effective for manufacturers and health agencies aiming to immunize every child.
• Opportunities and constraints regarding polio surveillance and monitoring technologies: Advanced surveillance technology is critical for global eradication, offering opportunities in genomic surveillance, diagnostic technologies, handheld health devices, and real-time reporting systems. Reinforcing surveillance networks is especially important in weak health system areas or where polio is still endemic. This creates opportunities for diagnostic testing services and data analysis.
• Polio vaccine manufacturing and supply chain improvements: The increasing demand for vaccines creates growth opportunities for manufacturing and distribution. Improving vaccine formulation and supply chain management is critical for consistent supply, especially in remote or conflict-affected regions. Collaboration between public health agencies and private companies will enhance market profitability and effectiveness.
• Public-private partnerships for polio eradication: PPPs have become effective in increasing vaccination coverage in underserved regions. These partnerships enable increased funding, resource sharing, and expertise, helping to overcome geographical and financial barriers. Securing investments through these partnerships enhances rapid deployment, infrastructure development, and manufacturing expansion.

The scenario of the poliomyelitis vaccine market globally looks favorable, with several growth opportunities such as vaccine proliferation, collaboration with other vaccine programs, technology integration for surveillance, improved manufacturing processes, and public-private partnerships. These opportunities support efforts to achieve polio eradication and sustained immunity in the post-eradication period. Synergistic actions between manufacturers, international health bodies, and governments are essential for enhancing vaccination, supply chain management, and surveillance.

Poliomyelitis Vaccine Market Driver and Challenges

There are many factors affecting the global market of poliomyelitis vaccines, including technological innovations, economic factors, and regulations. These factors influence vaccine purchase, vaccination processes, and the effectiveness of global eradication efforts. However, there are setbacks such as vaccine-derived poliovirus outbreaks, logistical issues, and regional heterogeneity in immunization, which remain challenges. It is important to assess and understand the factors driving and restraining the poliomyelitis vaccine market to succeed.

The factors responsible for driving the Poliomyelitis Vaccine market include:

1. Global campaigns for polio eradication: Led by the Global Polio Eradication Initiative (GPEI), involving WHO, UNICEF, and the Rotary Foundation, supported by substantial funding and political will, improving vaccination levels and supply, and establishing demand for OPV and IPV.

2. Shift toward IPV: The transition from OPV to IPV in immunization programs, especially in polio-free countries, to address VDPV concerns, increasing demand for IPV vaccines.

3. Technological advancements in vaccine production: Innovations such as recombinant DNA, adjuvants, and new formulations reduce costs and increase vaccine availability, especially in poor and conflict-affected regions.

4. Enhanced vaccine availability in developing economies: Initiatives like GAVI make vaccines accessible at reasonable prices, helping restore coverage in endemic areas.

5. Global networking and financial support: International funding and sponsorship support ongoing vaccination, research, and health system strengthening.

Challenges include:

1. Vaccine-derived poliovirus (VDPV): Outbreaks of VDPV, especially with OPV, pose a major obstacle. WHO advocates for IPV to eliminate this risk, but high costs and logistical issues hinder widespread adoption.

2. Logistical challenges: Distribution issues in rural and conflict zones, cold chain problems, wastage, and transportation hurdles.

3. Political conditions and conflict zones: Ongoing violence and conflict, especially in Afghanistan and Pakistan, hinder vaccination efforts.

International cooperation, improved mechanisms, and persistent efforts are necessary to eradicate poliomyelitis globally. Addressing challenges like VDPV, logistics, and socio-political issues is crucial for effective immunization programs.

List of Poliomyelitis Vaccine Companies

Companies in the market compete based on product quality. Major players focus on expanding manufacturing, R&D, infrastructure, and leveraging integration across the value chain. These strategies help cater to increasing demand, develop innovative products, reduce costs, and expand customer bases. Some of the companies profiled include:

• GSK
• Sanofi-Pasteur
• Merck
• Crucell
• China National Biotech Group

Poliomyelitis Vaccine Market by Segment

The study includes a forecast for the global poliomyelitis vaccine market by type, application, and region.

Poliomyelitis Vaccine Market by Type [Value from 2019 to 2031]:

• Poliomyelitis Vaccine I
• Poliomyelitis Vaccine II
• Poliomyelitis Vaccine III
• Oral Poliomyelitis Vaccine

Poliomyelitis Vaccine Market by Application [Value from 2019 to 2031]:

• VAPP
• VDPV

Poliomyelitis Vaccine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market has been a concern for numerous decades. The highly contagious disease, if left unmanaged, can lead to death or paralysis. Efforts to eliminate the disease have been mostly successful owing to advancements in polio vaccines. In countries such as the USA, China, Germany, India, and Japan, recent advancements focus on expanding vaccine distribution, managing outbreaks, and providing assistance with the last phase of elimination. Improvements in diffusion methods and timing, localized educational programs, and closer collaboration between global health agencies are expected to advance vaccination efforts in these areas.

• United States: Despite being at the forefront of polio vaccination and eradication efforts, occasional outbreaks from vaccine strains occur due to OPV. Prevention strategies include promoting IPV use. The CDC has expanded surveillance systems, ensured robust vaccination programs, and supports global eradication efforts. Maintaining polio-free certification through continuous investments and immunity is paramount.
• China: China has made significant progress in combating poliomyelitis, switching from OPV to IPV in 2016. Efforts include enhancing immunization systems, routine vaccination coverage, and vaccine supply chain management. China collaborates with WHO and other organizations, though challenges remain in large rural populations and migration.
• Germany: Germany remains a key player in global polio eradication, vaccinating with IPV only, maintaining high coverage, and participating in campaigns like GPEI. The country emphasizes awareness among migrants to ensure access to vaccination. Its strong healthcare system supports these efforts.
• India: India was declared polio-free in 2014 after decades of vaccination campaigns. Current efforts focus on maintaining this status and increasing immunization coverage, especially among marginalized and rural communities, with active government involvement.
• Japan: Japan has maintained excellent polio vaccination coverage for decades, employing IPV-only strategies. It supports international campaigns and has strengthened its health system to prevent reintroduction, serving as a leader in global health.

Features of the Global Poliomyelitis Vaccine Market

• Market Size Estimates: Estimation of market size in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by segments and regions.
• Segmentation Analysis: Market size by type, application, and region in dollar value.
• Regional Analysis: Breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities across types, applications, and regions.
• Strategic Analysis: Includes M&A, new product development, and competitive landscape.

Industry competitiveness based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the poliomyelitis vaccine market by type (poliomyelitis vaccine I, II, III, and oral poliomyelitis vaccine), application (VAPP and VDPV), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Poliomyelitis Vaccine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Poliomyelitis Vaccine I: Trends and Forecast (2019-2031)
• 4.4 Poliomyelitis Vaccine II: Trends and Forecast (2019-2031)
• 4.5 Poliomyelitis Vaccine III: Trends and Forecast (2019-2031)
• 4.6 Oral Poliomyelitis Vaccine: Trends and Forecast (2019-2031)

5. Global Poliomyelitis Vaccine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 VAPP: Trends and Forecast (2019-2031)
• 5.4 VDPV: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Poliomyelitis Vaccine Market by Region

7. North American Poliomyelitis Vaccine Market

• 7.1 Overview
• 7.2 North American Poliomyelitis Vaccine Market by Type
• 7.3 North American Poliomyelitis Vaccine Market by Application
• 7.4 United States Poliomyelitis Vaccine Market
• 7.5 Mexican Poliomyelitis Vaccine Market
• 7.6 Canadian Poliomyelitis Vaccine Market

8. European Poliomyelitis Vaccine Market

• 8.1 Overview
• 8.2 European Poliomyelitis Vaccine Market by Type
• 8.3 European Poliomyelitis Vaccine Market by Application
• 8.4 German Poliomyelitis Vaccine Market
• 8.5 French Poliomyelitis Vaccine Market
• 8.6 Spanish Poliomyelitis Vaccine Market
• 8.7 Italian Poliomyelitis Vaccine Market
• 8.8 United Kingdom Poliomyelitis Vaccine Market

9. APAC Poliomyelitis Vaccine Market

• 9.1 Overview
• 9.2 APAC Poliomyelitis Vaccine Market by Type
• 9.3 APAC Poliomyelitis Vaccine Market by Application
• 9.4 Japanese Poliomyelitis Vaccine Market
• 9.5 Indian Poliomyelitis Vaccine Market
• 9.6 Chinese Poliomyelitis Vaccine Market
• 9.7 South Korean Poliomyelitis Vaccine Market
• 9.8 Indonesian Poliomyelitis Vaccine Market

10. ROW Poliomyelitis Vaccine Market

• 10.1 Overview
• 10.2 ROW Poliomyelitis Vaccine Market by Type
• 10.3 ROW Poliomyelitis Vaccine Market by Application
• 10.4 Middle Eastern Poliomyelitis Vaccine Market
• 10.5 South American Poliomyelitis Vaccine Market
• 10.6 African Poliomyelitis Vaccine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Poliomyelitis Vaccine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 GSK
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Sanofi-Pasteur
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Merck
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Crucell
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 China National Biotech Group
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us